CoChat

Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis

Open access
Liu, Peng, Qian, Yerong, Liu, Xin, Zhu, Xulong, Zhang, Xufeng, Lv, Yi, Xiang, Junxi · 2023 · Frontiers in Immunology
Cited by 37

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Liver fibrosis is a fibrogenic and inflammatory process that results from hepatocyte injury and is characterized by hepatic architectural distortion and resultant loss of liver function. There is no effective treatment for advanced fibrosis other than liver transplantation, but it is limited by expensive costs, immune rejection, and postoperative complications. With the development of regenerative medicine in recent years, mesenchymal stem cell (MSCs) transplantation has become the most promising treatment for liver fibrosis. The underlying mechanisms of MSC anti-fibrotic effects include hepatocyte differentiation, paracrine, and immunomodulation, with immunomodulation playing a central role. This review discusses the immune cells involved in liver fibrosis, the immunomodulatory properties of MSCs, and the immunomodulation mechanisms of MSC-based strategies to attenuate liver fibrosis. Meanwhile, we discuss the current challenges and future directions as well.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2022.1096402

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 37

Metadata

Authors
Liu, P., Qian, Y., Liu, X., Zhu, X., Zhang, X., Lv, Y., & Xiang, J.
Venue
Frontiers in Immunology
Published
2023-01-04
Volume
13
Pages
1096402-1096402
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4313585893
Cited by
37
References
26
FWCI
5.13
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis. https://app.cochat.ai/papers/10.3389/fimmu.2022.1096402
The paper
Liu, P., Qian, Y., Liu, X., Zhu, X., Zhang, X., Lv, Y., & Xiang, J. (2023). Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.1096402

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.